These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31773183)

  • 1. Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats.
    Aggarwal D; Singh G
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):615-627. PubMed ID: 31773183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation.
    Barrera-Chimal J; Rocha L; Amador-Martínez I; Pérez-Villalva R; González R; Cortés-González C; Uribe N; Ramírez V; Berman N; Gamba G; Bobadilla NA
    Nephrol Dial Transplant; 2019 May; 34(5):794-801. PubMed ID: 30107561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.
    Mejía-Vilet JM; Ramírez V; Cruz C; Uribe N; Gamba G; Bobadilla NA
    Am J Physiol Renal Physiol; 2007 Jul; 293(1):F78-86. PubMed ID: 17376767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease.
    Rodríguez-Romo R; Benítez K; Barrera-Chimal J; Pérez-Villalva R; Gómez A; Aguilar-León D; Rangel-Santiago JF; Huerta S; Gamba G; Uribe N; Bobadilla NA
    Kidney Int; 2016 Feb; 89(2):363-73. PubMed ID: 26509589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
    Slagman MC; Navis G; Laverman GD
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury.
    Fouad AA; Qureshi HA; Al-Sultan AI; Yacoubi MT; Al-Melhim WN
    Pharmacology; 2010; 85(3):158-67. PubMed ID: 20150754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system blockade alone or combined with ET
    Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
    Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ageing reduces angiotensin II type 1 receptor antagonism mediated pre-conditioning effects in ischemic kidneys by inducing oxidative and inflammatory stress.
    Ogbadu J; Singh G; Gupta K; Mehra K; Sen P
    Exp Gerontol; 2020 Jul; 135():110892. PubMed ID: 32119995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of GABAergic activity of sodium valproate against ischemia-reperfusion-induced acute kidney injury in rats.
    Brar R; Singh JP; Kaur T; Arora S; Singh AP
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Feb; 387(2):143-51. PubMed ID: 24154851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury.
    Barrera-Chimal J; Pérez-Villalva R; Rodríguez-Romo R; Reyna J; Uribe N; Gamba G; Bobadilla NA
    Kidney Int; 2013 Jan; 83(1):93-103. PubMed ID: 23014458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of naringin, a bioflavonoid on ischemia-reperfusion induced renal injury in rats.
    Singh D; Chopra K
    Pharmacol Res; 2004 Aug; 50(2):187-93. PubMed ID: 15177308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
    Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
    J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Inflammation after Ischemia-Reperfusion of the Kidney: Role of the Sympathetic Nervous System and the Renin-Angiotensin System.
    Panico K; Abrahão MV; Trentin-Sonoda M; Muzi-Filho H; Vieyra A; Carneiro-Ramos MS
    Cell Physiol Biochem; 2019; 53(4):587-605. PubMed ID: 31535830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crocin reverses unilateral renal ischemia reperfusion injury-induced augmentation of oxidative stress and toll like receptor-4 activity.
    Abou-Hany HO; Atef H; Said E; Elkashef HA; Salem HA
    Environ Toxicol Pharmacol; 2018 Apr; 59():182-189. PubMed ID: 29625388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin 2 type 1 receptor blockade different affects postishemic kidney injury in normotensive and hypertensive rats.
    Miloradović Z; Ivanov M; Jovović Đ; Karanović D; Vajić UJ; Marković-Lipkovski J; Mihailović-Stanojević N; Milanović JG
    J Physiol Biochem; 2016 Dec; 72(4):813-820. PubMed ID: 27534651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual RAAS blockade is desirable in kidney disease: con.
    Bakris GL
    Kidney Int; 2010 Sep; 78(6):546-9. PubMed ID: 20664560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.
    Gupta G; Dahiya R; Singh Y; Mishra A; Verma A; Gothwal SK; Aljabali AAA; Dureja H; Prasher P; Negi P; Kapoor DN; Goyal R; Tambuwala MM; Chellappan DK; Dua K
    Chem Biol Interact; 2020 Feb; 317():108975. PubMed ID: 32032593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.